TEL AVIV, Israel–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) introduced as we speak that it’s going to challenge a press launch on its first quarter 2024 monetary outcomes on Wednesday, Might 8, 2024, at 7:00 a.m. ET. Following the discharge, Teva will conduct a convention name and stay webcast on the identical day, at 8:00 a.m. ET.
As a way to take part, please register prematurely right here to acquire an area or toll-free telephone quantity and your private pin.
A stay webcast of the decision might be accessible on Teva’s web site at: https://ir.tevapharm.com/Occasions-and-Shows
Following the conclusion of the decision, a replay of the webcast might be accessible inside 24 hours on Teva’s web site.
About Teva
Teva Pharmaceutical Industries (NYSE:) Ltd. (NYSE and TASE: TEVA) is a worldwide pharmaceutical chief with a category-defying portfolio, harnessing our generics experience and stepping up innovation to proceed the momentum behind the invention, supply, and expanded growth of recent drugs. For over 120 years, Teva’s dedication to bettering well being has by no means wavered. Right this moment, the corporate’s world community of capabilities allows its 37,000 staff throughout 58 markets to push the boundaries of scientific innovation and ship high quality medicines to assist enhance well being outcomes of thousands and thousands of sufferers each day. To study extra about how Teva is all in for higher well being, go to www.tevapharm.com.
Cautionary Be aware Concerning Ahead-Trying Statements
This doc and the convention name, might include forward-looking statements inside the which means of the Non-public Securities Litigation Reform Act of 1995, that are primarily based on administration’s present beliefs and expectations and are topic to substantial dangers and uncertainties, each identified and unknown, that would trigger our future outcomes, efficiency or achievements to vary considerably from that expressed or implied by such forward-looking statements. Essential elements that would trigger or contribute to such variations embrace dangers regarding: our means to efficiently compete within the market; our substantial indebtedness; our enterprise and operations basically; compliance, regulatory and litigation issues; different monetary and financial dangers; and different elements mentioned on this press launch and in our Annual Report on Kind 10-Ok for the 12 months ended December 31, 2023, together with within the sections captioned “Danger Components. Ahead-looking statements communicate solely as of the date on which they’re made, and we assume no obligation to replace or revise any forward-looking statements or different data contained herein, whether or not on account of new data, future occasions or in any other case. You’re cautioned to not put undue reliance on these forward-looking statements.
View supply model on businesswire.com: https://www.businesswire.com/information/house/20240409674024/en/
IR
Ran Meir
+1 (267) 468-4475
Yael Ashman
+972 (3) 914 8262
Sanjeev Sharma
+1 (973) 658 2700
PR
Kelley Dougherty
+1 (973) 832-2810
Eden Klein
+972 (3) 906 2645
Supply: Teva Pharmaceutical Industries Restricted
